Anti-thyroglobulin T cell receptors

A method of treating cancer in a mammal in need thereof, comprising administering to the mammal

• (a) one or more host cells expressing at least one of (i)-(vi):
• (i) a T cell receptor (TCR) having antigenic specificity for the amino acid sequence of SEQ ID NO:
• 2 and comprising an α chain complementarity determining region (CDR) 1 comprising the amino acid sequence of SEQ ID NO:
• 3, an α chain CDR2 comprising the amino acid sequence of SEQ ID NO:
• 4, an α chain CDR3 comprising the amino acid sequence of SEQ ID NO:
• 5, a β chain CDR1 comprising the amino acid sequence of SEQ ID NO:
• 6, a β chain CDR2 comprising the amino acid sequence of SEQ ID NO:
• 7, and a β chain CDR3 comprising the amino acid sequence of SEQ ID NO:
• 8,
• (ii) a polypeptide comprising a functional portion of the TCR of (i), wherein the functional portion comprises the amino acid sequences of SEQ ID NOs:
• 3-8,
• (iii) a polypeptide comprising a functional portion of the TCR of (i), wherein the functional portion comprises the amino acid sequence of both SEQ ID NOs:
• 9 and 10,
• (iv) a polypeptide comprising a functional portion of the TCR of (i), wherein the functional portion comprises the amino acid sequence of both SEQ ID NOs:
• 11 and 12,
• (v) a protein comprising at least one of the polypeptides of any one of (ii)-(iv), and
• (vi) a protein comprising a first polypeptide chain comprising the amino acid sequences of SEQ ID NOs:
• 3-5 and a second polypeptide chain comprising the amino acid sequences of SEQ ID NOs:
• 6-8, or
• (b) a pharmaceutical composition comprising the one or more cells of (a) and a pharmaceutically acceptable carrier
• in an amount effective to treat the cancer in the mammal, wherein the cancer expresses a human thyroglobulin (hTG) peptide comprising an amino acid sequence of SEQ ID NO:
• 2.